Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter‐Defibrillators in the Cardiovascular Research Network

Autor: Robert T. Greenlee, Alan S. Go, Pamela N. Peterson, Andrea E. Cassidy‐Bushrow, Charles Gaber, Romel Garcia‐Montilla, Karen A. Glenn, Nigel Gupta, Jerry H. Gurwitz, Stephen C. Hammill, John J. Hayes, Alan Kadish, David J. Magid, David D. McManus, Deborah Multerer, J. David Powers, Liza M. Reifler, Kristi Reynolds, Claudio Schuger, Param P. Sharma, David H. Smith, Mary Suits, Sue Hee Sung, Paul D. Varosy, Humberto J. Vidaillet, Frederick A. Masoudi
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Zdroj: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 7 (2018)
Druh dokumentu: article
ISSN: 2047-9980
04854721
DOI: 10.1161/JAHA.117.008292
Popis: BackgroundPrimary prevention implantable cardioverter‐defibrillators (ICDs) reduce mortality in selected patients with left ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in 7 healthcare systems. Methods and ResultsWe linked medical record data, adjudicated device therapies, and the National Cardiovascular Data Registry ICD Registry. Survival analysis evaluated therapy probability and predictors after ICD implant from 2006 to 2009, with attention to Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups: left ventricular ejection fraction, 31% to 35%; nonischemic cardiomyopathy
Databáze: Directory of Open Access Journals
Externí odkaz: